Frankfurt
27.06.25 | 15:29
4,000 Euro
-0,99 % -0,040
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.06. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 2 | GlobeNewswire (USA) | ||
| 10.06. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 21.05. | Nanobiotix S.A. reports Q1 results | 4 | Seeking Alpha | ||
| 21.05. | Nanobiotix S.A.: Nanobiotix Provides First Quarter 2025 Operational and Financial Update | 128 | GlobeNewswire (Europe) | Dosing of a first patient in the CONVERGE study, a Phase 2 randomized controlled clinical trial for patients with stage 3 unresectable non-small cell lung cancerPresentation of data at the European... ► Artikel lesen | |
| 21.05. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 14.05. | Nanobiotix S.A. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 14.05. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 1 | GlobeNewswire (USA) | ||
| NANOBIOTIX SA ADR Aktie jetzt für 0€ handeln | |||||
| 12.05. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 05.05. | Nanobiotix Reveals Favorable Results Of JNJ-1900 Study Pancreatic Cancer; Seeks Further Evaluation | 379 | AFX News | NEW BRUNSWICK (dpa-AFX) - Nanobiotix S.A. (NBTX), a biotechnology company focused on nanoparticle-based cancer treatments, announced Monday positive full results from the completed dose escalation... ► Artikel lesen | |
| 05.05. | Nanobiotix S.A.: Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer | 255 | GlobeNewswire (Europe) | Results demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients (n=22) with locally advanced or borderline resectable pancreatic cancerMedian Overall Survival... ► Artikel lesen | |
| 30.04. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 14.04. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 2 | GlobeNewswire (USA) | ||
| 10.04. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 04.04. | Guggenheim cuts Nanobiotix stock target to $8, maintains buy | 5 | Investing.com | ||
| 02.04. | Nanobiotix GAAP EPS of -€1.44 | 1 | Seeking Alpha | ||
| 02.04. | Nanobiotix S.A. - 20-F, Annual and transition report of foreign private issuers | 2 | SEC Filings | ||
| 02.04. | Nanobiotix S.A.: NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results | 129 | GlobeNewswire (Europe) | Global development program for JNJ-1900 (NBTXR3) proceeding as planned, with opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and... ► Artikel lesen | |
| 31.03. | Nanobiotix S.A.: NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025 | 1 | GlobeNewswire (USA) | ||
| 27.03. | Nanobiotix reports promising NSCLC treatment study results | 1 | Investing.com | ||
| 27.03. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 0,120 | -1,64 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,680 | -8,22 % | COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders | Reconstituted Board to Revitalize COSCIENS TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) today announced that it has entered into a resolution agreement... ► Artikel lesen | |
| AMYRIS | - | - | Amyris gains sole control of Brazilian fermentation facility | ||
| HALOZYME THERAPEUTICS | 45,050 | +0,92 % | Halozyme Says Bristol-Myers Squibb Gets EC Approval For Opdivo SC Developed With Halozyme's ENHANZE | NEW YORK CITY (dpa-AFX) - Halozyme Therapeutics, Inc. (HALO) Wednesday said that Bristol-Myers Squibb Company (BMY) received approval from the European Commission (EC) for a new subcutaneous... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 3,044 | -1,17 % | AbCellera-Aktionäre genehmigen Vorstandswahl und Wirtschaftsprüfer | ||
| GLOW LIFETECH | 0,021 | +7,89 % | Glow Lifetech Corp.: Glow Lifetech Provides Commercial Update; Expands to 1000+ Stores in Ontario and Achieves #2 Oil Brand with MOD | Toronto, Ontario--(Newsfile Corp. - June 23, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to provide a commercial update reflecting its... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 205,80 | -1,25 % | Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results | HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results... ► Artikel lesen | |
| AVID BIOSERVICES | 12,100 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 05.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 05.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 05.02.2025ISIN NameCA75525M1095 RAZOR... ► Artikel lesen | |
| BIOLINERX | 3,283 | -100,00 % | BioLineRx Ltd: BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting | - 4 of 11 PDAC patients in the pilot phase remained progression free at over one year
- Poster presentation on Saturday, May 31 st
TEL AVIV, Israel, May 30, 2025... ► Artikel lesen | |
| WHITEHAWK THERAPEUTICS | 1,570 | +2,61 % | Whitehawk Therapeutics, Inc.: Whitehawk Reports First Quarter 2025 Financial Results and Recent Highlights | MORRISTOWN, N.J., May 8, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to... ► Artikel lesen | |
| PARATEK PHARMACEUTICALS | - | - | Paratek Pharmaceuticals, Inc.: Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE in Chronic Rhinosinusitis (CRS) | Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10-million-patient marketAcquisition advances Paratek's vision... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 1,520 | +0,66 % | Minerva Neurosciences, Inc: Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates | BURLINGTON, Mass., May 13, 2025(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates... ► Artikel lesen | |
| APPLIED THERAPEUTICS | 0,312 | +6,64 % | Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting | Slowing of progression of disease observed via MRI at 24 months Improvements in outcomes and reduction in sorbitol maintained through 24 months Statistically significant correlation between absolute... ► Artikel lesen | |
| GEOVAX LABS | 2,685 | -100,00 % | GeoVax Labs, Inc. - S-1/A, General form for registration of securities | ||
| COCRYSTAL | 1,240 | 0,00 % | Cocrystal Pharma, Inc.: Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants | Norovirus GII.17 variants have overtaken GII.4 as the most prevalent strain and significantly increased norovirus outbreaks in the U.S. and European countries in 2024-2025Cocrystal Pharma's pan-viral... ► Artikel lesen |
Das Unternehmen NANOBIOTIX SA ADR kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,99 % bei einem Aktienkurs von 4,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOBIOTIX SA ADR finden Sie auf Wallstreet Online.